1. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom
  2. Dietary Flavonoid and Proanthocyanidin Intakes and Prostate Cancer Risk in a Prospective Cohort of US Men
  3. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease
  4. Can Supervised Exercise Prevent Treatment Toxicity in Prostate Cancer Patients Initiating Androgen Deprivation Therapy: A Randomised Controlled Trial
  5. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
  6. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study
  7. Overdiagnosis and Overtreatment of Prostate Cancer
  8. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
  9. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer
  10. Chemotherapy and its evolving role in the management of advanced prostate cancer
  11. Is Intermittent Androgen Deprivation Therapy Beneficial For Advanced Prostate Cancer Patients?
  12. Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
  13. Molecular alterations and emerging targets in castration resistant prostate cancer
  14. Anxiety level of early- and late-stage prostate cancer patients
  15. Bone-targeting agents in prostate cancer
  16. Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
  17. Estrogen receptor beta in prostate cancer: friend or foe?
  18. Treatment planning for prostate focal laser ablation in the face of needle placement uncertainty
  19. Advances in Robotic-Assisted Radical Prostatectomy over Time
  20. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer
  21. Toward a common therapeutic framework in castration-resistant prostate cancer: A model for urologic oncology and medical oncology interaction
  22. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy
  23. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013
  24. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies
  25. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer
  26. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
  27. Racial Differences in Longitudinal Changes in Serum Prostate-specific Antigen Levels: The Olmsted County Study and the Flint Men's Health Study
  28. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients
  29. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer
  30. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling
  31. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
  32. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
  33. Clinicopathological Characteristics of Incidental Prostate Cancer Discovered from Radical Cystoprostatectomy Specimen: A Multicenter French Study
  34. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer
  35. Next-generation therapy for residual prostate cancer
  36. Future Directions From Past Experience: A Century of Prostate Radiotherapy
  37. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options
  38. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
  39. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer
  40. The Prevalence of the HOXB13 G84E Prostate Cancer Risk Allele in Men Treated with Radical Prostatectomy
  41. Prostate cancer patients continue to have excess mortality up to 15 years after diagnosis
  42. Complete regression of advanced prostate cancer for ten years: A case report and review of the literature
  43. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis
  44. Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid
  45. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
  46. Chemoprevention of prostate cancer by major dietary phytochemicals
  47. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry
  48. Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland
  49. Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial
  50. Prostate cancer and the increasing role of active surveillance
  51. Early human prostate adenocarcinomas harbor androgen-independent cancer cells
  52. Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy
  53. Idiopathic intracranial hypertension: A possible complication in the natural history of advanced prostate cancer
  54. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer
  55. Locally advanced prostate cancer: optimal therapy in older patients
  56. Bilateral cancer in prostate biopsy associates with the presence of extracapsular disease and positive surgical margins in low risk patients: a consideration for bilateral nerve sparing radical prostatectomy decision
  57. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
  58. Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning
  59. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies
  60. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients
  61. Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
  62. Pathological and Oncological Outcomes of Elderly Men with Clinically Localized Prostate Cancer
  63. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
  64. Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial
  65. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer
  66. Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
  67. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience
  68. Influence of obesity on localized prostate cancer patients treated with radical prostatectomy
  69. Racial Differences in Longitudinal Changes in Serum Prostate-specific Antigen Levels: The Olmsted County Study and the Flint Men's Health Study
  70. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
  71. The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates
  72. A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications
  73. Evolution of advanced technologies in prostate cancer radiotherapy
  74. Tasquinimod: a novel drug in advanced prostate cancer
  75. Agonists of luteinizing hormone-releasing hormone in prostate cancer
  76. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management
  77. Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
  78. Results of Radical Prostatectomy in Newly Diagnosed Prostate Cancer: Long-term Survival Rates in Locally Advanced and High-Risk Cancers
  79. The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review
  80. Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer
  81. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study
  82. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
  83. Epidural Analgesia during Open Radical Prostatectomy Does Not Improve Long-Term Cancer-Related Outcome: A Retrospective Study in Patients with Advanced Prostate Cancer
  84. Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer
  85. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer
  86. Variations in cancer survival and patterns of care across europe: roles of wealth and health-care organization
  87. Mediterranean Diet and Prostate Cancer Risk and Mortality in the Health Professionals Follow-up Study
  88. Total antioxidant intake in relation to prostate cancer incidence in the health professionals follow up study
  89. Adaptive radiotherapy in locally advanced prostate cancer using a statistical deformable motion model
  90. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate
  91. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials
  92. Gleason Grade Progression Is Uncommon
  93. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies
  94. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer
  96. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers
  97. Length of prostate biopsy cores: does it impact cancer detection?
  98. Alcohol and smoking and subsequent risk of prostate cancer in Japanese men: The Japan Public Health Center-based prospective study
  99. Effect of physical exercise on muscle mass and strength in cancer patients during treatment-A systematic review
  100. Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma
  101. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments
  102. Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update
  103. Variation in Treatment Recommendations of Adjuvant Radiation Therapy for High-risk Prostate Cancer by Physician Specialty
  104. Recent advances revolutionize treatment of metastatic prostate cancer
  105. Efficacy of Intermittent Androgen Deprivation Therapy vs Conventional Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Meta-analysis
  106. Dietary antioxidants and prostate cancer: a review
  107. Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy
  108. High nuclear karyopherin ? 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy
  109. Advanced Prostate Cancer Risk in Relation to Toenail Selenium Levels
  110. Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy
  111. Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer
  112. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer
  113. Dietary factors and risk for advanced prostate cancer
  114. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer
  115. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
  116. Dietary factors and risk for advanced prostate cancer
  117. Is there room for combined modality treatments? Dosimetric comparison of boost strategies for advanced head and neck and prostate cancer
  118. Early detection of prostate cancer: European association of urology recommendation
  119. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
  120. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
  121. GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer
  122. Analysis of docetaxel therapy in elderly (?70years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study
  123. The Influence of Prostate Volume on Outcome After High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer
  124. Seminal plasma as a source of prostate cancer Peptide biomarker candidates for detection of indolent and advanced disease
  125. Metabolomic signatures of aggressive prostate cancer
  126. A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
  127. The utility of prostate-specific antigen in the management of advanced prostate cancer
  128. An integrative review of nursing research on active surveillance in an older adult prostate cancer population
  129. Emerging molecularly targeted therapies in castration refractory prostate cancer
  130. Pushing the limits of radiation therapy for prostate cancer: where do we go next?
  131. Multimodality therapy for patients with high-risk prostate cancer: current status and future directions
  132. Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?
  133. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
  134. Recurrent deletion of 3p13 targets multiple tumor suppressor genes and defines a distinct subgroup of aggressive ERG fusion positive prostate cancers
  135. Use of advanced treatment technologies among men at low risk of dying from prostate cancer
  136. Abiraterone for the Treatment of Advanced Prostate Cancer
  137. Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy
  138. PSA screening for prostate cancer: why so much controversy?
  139. Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population
  140. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
  141. ERG Protein Expression and Gene Rearrangements are Present at Lower Rates in Metastatic and Locally Advanced Castration-resistant Prostate Cancer Compared to Localized Disease
  142. Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
  143. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
  144. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
  145. Advances in the treatment of metastatic prostate cancer
  146. Dietary flavonoid intake, black tea consumption, and risk of overall and advanced stage prostate cancer
  147. An androgen receptor N-terminal domain antagonist for treating prostate cancer
  148. Sixth Joint Meeting of J-CaP and CaPSURE--A Multinational Perspective on Prostate Cancer Management and Patient Outcomes
  149. Individualized image-based lymph node irradiation for prostate cancer
  150. Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study
  151. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
  152. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
  153. Individualized image-based lymph node irradiation for prostate cancer
  154. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy
  155. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification
  156. Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-?B Ligand Inhibitors in Patients with Advanced Prostate Cancer
  157. Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer
  158. Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone
  159. Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study
  160. Locally Advanced Prostate Cancer: Current Controversies and Optimisation Opportunities
  161. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer
  162. High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy
  163. Plasma levels of nitrate and risk of prostate cancer: a prospective study
  164. MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know
  165. Results of hormone therapy as first-line treatment for high-risk prostate cancer
  166. The Future of Systemic Therapies for Localised Prostate Cancer
  167. Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands
  168. A review of tasquinimod in the treatment of advanced prostate cancer
  169. Bone markers for monitoring efficacy in patients ?with bone metastases receiving zoledronic acid: ?a review of published data
  170. Clinical Significance of Wnt/?-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer
  171. Sleep disruption among older men and risk of prostate cancer
  172. Unmet Needs in the Prediction and Detection of Metastases in Prostate Cancer
  173. Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy
  174. The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-resistant Prostate Cancer
  175. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
  176. Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer
  177. Androgens Upregulate Cdc25C Protein by Inhibiting Its Proteasomal and Lysosomal Degradation Pathways
  178. New paradigms in microtubule-mediated endocrine signaling in prostate cancer
  179. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - A cross-sectional study
  180. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
  181. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence
  182. Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer
  183. Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint
  184. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
  185. Zoledronic acid in genitourinary cancer
  186. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610
  187. Radiation therapy for prostate cancer
  188. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
  189. Minireview: The molecular and genomic basis for prostate cancer health disparities
  190. Consumption of Fish Products across the Lifespan and Prostate Cancer Risk
  191. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
  192. Prostate cancer and sexual function
  193. Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: A single-centre experience
  194. The Dilemma of Localizing Disease Relapse After Radical Treatment for Prostate Cancer: Which is The Value of The Actual Imaging Techniques?
  195. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis
  196. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: A study of adverse effects and their relation to quality of life
  197. Dietary Fat, Fatty Acids, and Risk of Prostate Cancer in the NIH-AARP Diet and Health Study
  198. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor
  199. Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness
  200. Intratumoral inflammation is associated with more aggressive prostate cancer
  201. Genes associated with prostate cancer are differentially expressed in African American and European American men
  202. Identification of prostate cancer risk categories according to surgical margins status, pathological stage and Gleason score
  203. Novel Immunotherapies in GU Malignancies
  204. Multidisciplinary care in patients with prostate cancer: room for improvement
  205. Comparison of Prostate-Specific Promoters and the Use of PSP-Driven Virotherapy for Prostate Cancer
  206. PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality
  207. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer
  208. Prostate Cancer Mortality in the Finnish Randomized Screening Trial
  209. Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study
  210. Prostate cancer vaccines: an old yet novel target, the androgen receptor
  211. Regional Variation in Spending and Survival for Older Adults With Advanced Cancer
  212. Increased incidence of pathologically nonorgan confined prostate cancer in african-american men eligible for active surveillance
  213. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
  214. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy
  215. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent
  216. Screening for prostate cancer
  217. The current role and limitations of surrogate endpoints in advanced prostate cancer
  218. Targeted radiosensitization in prostate cancer
  219. A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer
  220. Predicting high risk disease using serum and DNA biomarkers
  221. Predicting high risk disease using serum and DNA biomarkers
  222. Impact of Advanced Age on Biochemical Recurrence After Radical Prostatectomy in Japanese Men According to Pathological Stage
  223. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer
  224. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence
  225. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression
  226. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
  227. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison
  228. Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
  229. 11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction
  230. Molecular Pathways: Inhibiting steroid biosynthesis in prostate cancer
  231. Experience with degarelix in the treatment of prostate cancer
  232. Late radiation effects to the rectum and anus after treatment for prostate cancer; validity of the LENT/SOMA score
  233. ACR Appropriateness Criteria Prostate Cancer-Pretreatment Detection, Staging, and Surveillance
  234. The importance of local control in high-risk locally advanced prostate cancer
  235. A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening
  236. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
  237. Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF
  238. Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective
  239. Health-related quality of life in prostate cancer
  240. Detection of circulating tumor cells in different stages of prostate cancer
  241. Understanding requirements of novel healthcare information systems for management of advanced prostate cancer
  242. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer
  243. Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer
  244. Treatment of locally advanced prostate cancer: a case report and narrative review
  245. Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
  246. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer
  247. Excess mortality in the evaluation of a screening trial - important to account for selective participation
  248. A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results
  249. Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy
  250. Tissue mimicking materials for the detection of prostate cancer using shear wave elastography: A validation study
  251. Androgen deprivation therapy toxicity and management for men receiving radiation therapy
  252. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer
  253. Agents that target androgen synthesis in castration-resistant prostate cancer.
  254. Androgen receptor antagonists in castration-resistant prostate cancer
  255. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial
  256. Novel Therapies for the Treatment of Advanced Prostate Cancer
  257. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions
  258. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
  259. Diabetes mellitus and prostate cancer risk of different grade or stage: A systematic review and meta-analysis
  260. Prostate cancer: ESMO Consensus Conference Guidelines 2012
  261. Radical prostatectomy in high-risk prostate cancer
  262. DAB2IP Regulates Autophagy in Prostate Cancer in Response to Combined Treatment of Radiation and a DNA-PKcs Inhibitor
  263. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
  264. New treatment developments applied to elderly patients with advanced prostate cancer
  265. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
  266. Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer
  267. Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers
  268. GreenLight HPS 120-W laser photoselective vaporization of the prostate as early therapy for acute urinary retention in advanced prostate cancer patients
  269. Severity of coronary artery disease and prostate-specific antigen relationship in men
  270. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?
  271. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer
  272. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice